QuickLinks -- Click here to rapidly navigate through this document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):March 26, 2004
VASO ACTIVE PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction
of Incorporation) | | 001-31925
(Commission
File Number) | | 02-0670926
(I.R.S. Employer
Identification No.) |
99 Rosewood Drive, Suite 260, Danvers, Massachusetts 01923
(Address of Principal Executive Offices) (Zip Code) |
Registrant's telephone number, including area code:(978) 750-1991
TABLE OF CONTENTS
| ITEM 9. REGULATION FD DISCLOSURE | | |
ITEM 7. EXHIBITS |
|
|
SIGNATURE |
|
|
EXHIBIT 99.1—SCRIPT FOR CONFERENCE CALL AND AUDIO WEBCAST HELD ON MARCH 26, 2004. |
|
|
2
ITEM 9. REGULATION FD DISCLOSURE
On March 26, 2004, Vaso Active Pharmaceuticals, Inc. (the "Company") broadcast its full year 2003 results and outlook for 2004 via a conference call and audio webcast conducted by Mr. John J. Masiz, President, Chairman and Chief Executive Officer. This call was webcast by CCBN and can be accessed at Vaso Active's web site atwww.vasoactive.us/vmir2.html.
ITEM 7. EXHIBITS
(c) Exhibits.
Exhibit 99.1—Script for conference call and audio webcast held on March 26, 2004.
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | VASO ACTIVE PHARMACEUTICALS, INC. |
|
|
By: |
/s/ JOHN J. MASIZ
Name: John J. Masiz
Title: President, CEO |
Date: March 26, 2004
4
QuickLinks
TABLE OF CONTENTSSIGNATURE
